Skip to main content
spacbrain

Zura Bio

Closed (deSPAC)

Health Care · clinical-stage biopharmaceutical development

What it is
Bio Limited Zura is a clinical-stage biotechnology company advancing two primary assets, including ZB-168 in Alopecia Areata and other inflammatory diseases and torudokimab in both chronic obstructive pulmonary disease (COPD) and asthma
What it’s doing now
Merging with JATT Acquisition Corp (ZURA) — closed (despac).
What you should know
The deal carries a $65M minimum-cash condition — heavy redemptions can break it.

The business, per its filings

SEC primary

Bio Limited Zura is a clinical-stage biotechnology company advancing two primary assets, including ZB-168 in Alopecia Areata and other inflammatory diseases and torudokimab in both chronic obstructive pulmonary disease (COPD) and asthma. ZB-168 is an anti IL7R α inhibitor that has the potential to impace diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168, and is focused on demonstrating its efficacy, safety, dosing convenience and mechanism of action, initially in Alopecia Areata (AA). This will build on Phase 1b data in Type 1 Diabetes demonstrating a favourable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at Phase 2 clinical development stage. IL33 is a validated drug target in both chronic obstructive pulmonary disease (COPD) and asthma. Zura is headquartered in London, UK. Zura is headquartered in London, UK

Source: S-4/A, accession 0001104659-23-024425

What the company says about itself

Web research — not audited

Zura Bio is a biotechnology company developing novel medicines for serious immune system disorders, specifically focusing on dual-pathway biology to treat severe autoimmune and inflammatory conditions. Their pipeline includes tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880). The company is publicly traded on Nasdaq under the ticker ZURA.

Markets:
Biotechnology | Pharmaceuticals | Autoimmune Disorders | Inflammatory Conditions
Products:
tibulizumab (ZB-106) | crebankitug (ZB-168) | torudokimab (ZB-880)
What our web check found

[WEB-INTEL 2026-08-26] 2 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "purchase price of $3.108 per share" [https://investors.zurabio.com/news-releases/news-release-details/zura-bio-announces-oversubscribed-1125-million-private-placement] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "In order to facilitate the completion of the Business Combination, on January 16, 2023, JATT, Merger Sub, Merger Sub 2, Zura and Holdco entered into the third ..." [https://investors.zurabio.com/node/6831/html]

Source: https://zurabio.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Zura Bio is merging with JATT Acquisition Corp (ZURA) currently marked Closed (deSPAC).

Headline equity value—
PIPE≈ $20M · unsourced
Minimum cash to close$65M

Structure per SEC accession(s) 0001104659-22-093035. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Zura Bio going public?

Zura Bio has an approved merger with the SPAC JATT Acquisition Corp (ZURA). Deal status: Closed (deSPAC).

Does Zura Bio have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals